Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Study of Nab-Paclitaxel (Nanoparticle Albumin Bound-Paclitaxel) in Patients With Advanced Solid Tumors
18 Years
N/A
Both
Cancer
Trial Information
Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Study of Nab-Paclitaxel (Nanoparticle Albumin Bound-Paclitaxel) in Patients With Advanced Solid Tumors
OBJECTIVES:
Primary
- To develop a population pharmacokinetic model for paclitaxel administered as paclitaxel
albumin-stabilized nanoparticle formulation (nab-paclitaxel) to a large population of
patients with advanced or refractory cancer to characterize the inter-individual
pharmacokinetic variability of this agent.
Secondary
- To explore nab-paclitaxel pharmacokinetic parameters in patients with metastatic
prostate cancer (castrate), metastatic breast cancer, advanced non-small cell lung
cancer and other incurable advanced or refractory tumors amenable to treatment with
nab-paclitaxel.
- To explore the association between exposure to total and unbound paclitaxel after
administration of nab-paclitaxel and neutropenia.
- To explore the association between the CYP2C8*3 variant and paclitaxel clearance.
- To explore the association between other variants of CYP2C8 and other genes involved in
paclitaxel disposition including CYP3A4, CYP3A5, SLCO1B3 (OATP8), and ABCB1 (MDR1) and
paclitaxel pharmacokinetic parameters and toxicity after one course of treatment.
OUTLINE: This is a multicenter study.
Patients receive paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel) IV
over 30 minutes on days 1, 8, 15, 22, 29, 36, 43, and 50. Treatment may repeat off study
every 9 weeks in the absence of disease progression or unacceptable toxicity.
Serial blood samplings are obtained at specified time points during course 1 including
baseline and days 1 and 8 of course 1 for pharmacokinetic studies. Samples are also examined
for genotype by PCR including variant genotypes in 2C8, CYP3A4, CYP3A5, ABCB1, ABCC2, ABCC10
and OATP1B3 genes.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Patients must have an incurable advanced or refractory tumor amenable to treatment
with paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel)
- Per the National Comprehensive Cancer Network, the following cancer sites have
been shown to be responsive to taxane therapy:
- Prostate cancer
- Breast cancer
- Non-small cell lung cancer
- Bladder cancer
- Head and neck cancer
- Oral cancer
- Cervical cancer
- Ovarian cancer
- Endometrial cancer
- Esophageal cancer
- Gastric cancer
- Germ cell tumors
- Tumors of unknown primary
- Soft tissue sarcomas
- Small cell lung cancer
- Testicular cancer
- Upper genitourinary tract cancers
PATIENT CHARACTERISTICS:
- Patients must have performance status 0-2 by the ECOG scale
- Absolute neutrophil count ≥ 1,500/μL
- Platelet count ≥ 100,000/μL
- Hemoglobin ≥ 9 g/dL
- Bilirubin ≤ institutional upper limit of normal (ULN)
- ALT and AST ≤ 2.5 x ULN
- Alkaline phosphatase ≤ 2.5 x ULN (if bone metastasis is present in the absence of
liver metastasis, alkaline phosphatase must be ≤ 5 x ULN)
- Creatinine ≤ 1.5 x ULN
- Patients must not have baseline sensory neuropathy ≥ grade 2
- Women must not be pregnant or breastfeeding
- Negative blood or urine pregnancy test
- Women of childbearing potential and sexually active males must agree to use an
accepted and effective method of contraception
PRIOR CONCURRENT THERAPY:
- Prior treatment is allowed, which may include prior taxane therapy
- If patient has had prior therapy(ies), s/he must have received last treatment ≥
28 days prior to registration
- Patients must not be receiving colony stimulating factors (CSFs)
- Previous CSFs must have been discontinued > 14 days prior to registration
- Patients must not be receiving concomitant treatment with any of the following (prior
use is allowed, but must have been discontinued ≥ 28 days prior to registration):
- Phenytoin
- Carbamazepine
- Barbiturates
- Rifampicin
- Phenobarbital
- Hypericum perforatum (St. John's wort)
- Ketoconazole
Type of Study:
Interventional
Study Design:
Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Inter-individual pharmacokinetic variability
Safety Issue:
No
Principal Investigator
Sridhar Mani, MD
Investigator Role:
Study Chair
Investigator Affiliation:
Albert Einstein College of Medicine of Yeshiva University
Authority:
Unspecified
Study ID:
CDR0000554709
NCT ID:
NCT00499291
Start Date:
September 2006
Completion Date:
Related Keywords:
- Cancer
- unspecified adult solid tumor, protocol specific
- recurrent breast cancer
- stage IIIA breast cancer
- stage IIIB breast cancer
- stage IIIC breast cancer
- recurrent prostate cancer
- stage III prostate cancer
- stage IV prostate cancer
- recurrent non-small cell lung cancer
- stage IIIA non-small cell lung cancer
- stage IIIB non-small cell lung cancer
- stage IV non-small cell lung cancer
- extensive stage small cell lung cancer
- recurrent small cell lung cancer
- recurrent bladder cancer
- stage III bladder cancer
- stage IV bladder cancer
- recurrent renal cell cancer
- stage III renal cell cancer
- stage IV renal cell cancer
- clear cell sarcoma of the kidney
- rhabdoid tumor of the kidney
- recurrent malignant testicular germ cell tumor
- stage III malignant testicular germ cell tumor
- recurrent cervical cancer
- stage III cervical cancer
- stage IVA cervical cancer
- stage IVB cervical cancer
- recurrent endometrial carcinoma
- stage III endometrial carcinoma
- stage IV endometrial carcinoma
- fallopian tube cancer
- recurrent ovarian epithelial cancer
- stage III ovarian epithelial cancer
- stage IV ovarian epithelial cancer
- recurrent ovarian germ cell tumor
- stage III ovarian germ cell tumor
- stage IV ovarian germ cell tumor
- ovarian sarcoma
- ovarian stromal cancer
- recurrent uterine sarcoma
- stage III uterine sarcoma
- stage IV uterine sarcoma
- recurrent hypopharyngeal cancer
- stage III hypopharyngeal cancer
- stage IV hypopharyngeal cancer
- recurrent laryngeal cancer
- stage III laryngeal cancer
- stage IV laryngeal cancer
- recurrent lip and oral cavity cancer
- stage III lip and oral cavity cancer
- stage IV lip and oral cavity cancer
- recurrent metastatic squamous neck cancer with occult primary
- untreated metastatic squamous neck cancer with occult primary
- recurrent nasopharyngeal cancer
- stage III nasopharyngeal cancer
- stage IV nasopharyngeal cancer
- recurrent oropharyngeal cancer
- stage III oropharyngeal cancer
- stage IV oropharyngeal cancer
- recurrent paranasal sinus and nasal cavity cancer
- stage III paranasal sinus and nasal cavity cancer
- stage IV paranasal sinus and nasal cavity cancer
- recurrent salivary gland cancer
- stage III salivary gland cancer
- stage IV salivary gland cancer
- recurrent esophageal cancer
- stage III esophageal cancer
- stage IV esophageal cancer
- recurrent gastric cancer
- stage III gastric cancer
- stage IV gastric cancer
- adult central nervous system germ cell tumor
- adult teratoma
- ovarian teratoma
- testicular teratoma
- recurrent adult soft tissue sarcoma
- stage III adult soft tissue sarcoma
- stage IV adult soft tissue sarcoma
- recurrent carcinoma of unknown primary
Name | Location |
|---|
